These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

496 related articles for article (PubMed ID: 30413151)

  • 1. A phase 3, long-term, open-label safety study of Galcanezumab in patients with migraine.
    Camporeale A; Kudrow D; Sides R; Wang S; Van Dycke A; Selzler KJ; Stauffer VL
    BMC Neurol; 2018 Nov; 18(1):188. PubMed ID: 30413151
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and tolerability of monthly galcanezumab injections in patients with migraine: integrated results from migraine clinical studies.
    Bangs ME; Kudrow D; Wang S; Oakes TM; Terwindt GM; Magis D; Yunes-Medina L; Stauffer VL
    BMC Neurol; 2020 Jan; 20(1):25. PubMed ID: 31952501
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial.
    Mulleners WM; Kim BK; Láinez MJA; Lanteri-Minet M; Pozo-Rosich P; Wang S; Tockhorn-Heidenreich A; Aurora SK; Nichols RM; Yunes-Medina L; Detke HC
    Lancet Neurol; 2020 Oct; 19(10):814-825. PubMed ID: 32949542
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Safety of Galcanezumab for the Preventive Treatment of Migraine: A Narrative Review.
    Martin V; Samaan KH; Aurora S; Pearlman EM; Zhou C; Li X; Pallay R
    Adv Ther; 2020 May; 37(5):2034-2049. PubMed ID: 32319039
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Galcanezumab in Patients with Multiple Previous Migraine Preventive Medication Category Failures: Results from the Open-Label Period of the CONQUER Trial.
    Reuter U; Lucas C; Dolezil D; Hand AL; Port MD; Nichols RM; Stroud C; Tockhorn-Heidenreich A; Detke HC
    Adv Ther; 2021 Nov; 38(11):5465-5483. PubMed ID: 34542830
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term treatment with galcanezumab in patients with chronic migraine: results from the open-label extension of the REGAIN study.
    Pozo-Rosich P; Detke HC; Wang S; Doležil D; Li LQ; Aurora SK; Reuter U
    Curr Med Res Opin; 2022 May; 38(5):731-742. PubMed ID: 35392739
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of Galcanezumab for the Prevention of Episodic Migraine: The EVOLVE-1 Randomized Clinical Trial.
    Stauffer VL; Dodick DW; Zhang Q; Carter JN; Ailani J; Conley RR
    JAMA Neurol; 2018 Sep; 75(9):1080-1088. PubMed ID: 29813147
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Galcanezumab in episodic migraine: the phase 3, randomized, double-blind, placebo-controlled PERSIST study.
    Hu B; Li G; Li X; Wu S; Yu T; Li X; Zhao H; Jia Z; Zhuang J; Yu S
    J Headache Pain; 2022 Jul; 23(1):90. PubMed ID: 35896988
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Galcanezumab in chronic migraine: The randomized, double-blind, placebo-controlled REGAIN study.
    Detke HC; Goadsby PJ; Wang S; Friedman DI; Selzler KJ; Aurora SK
    Neurology; 2018 Dec; 91(24):e2211-e2221. PubMed ID: 30446596
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of galcanezumab in patients with migraine who did not benefit from commonly prescribed preventive treatments.
    Kuruppu DK; Tobin J; Dong Y; Aurora SK; Yunes-Medina L; Green AL
    BMC Neurol; 2021 Apr; 21(1):175. PubMed ID: 33892641
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of age on pharmacokinetics, efficacy, and safety of galcanezumab treatment in adult patients with migraine: results from six phase 2 and phase 3 randomized clinical trials.
    Stauffer VL; Turner I; Kemmer P; Kielbasa W; Day K; Port M; Quinlan T; Camporeale A
    J Headache Pain; 2020 Jun; 21(1):79. PubMed ID: 32576229
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Galcanezumab in patients with episodic migraine: results from the open-label period of the phase 3 PERSIST study.
    Zhou J; Zhong L; Chowdhury D; Skorobogatykh K; Luo G; Yang X; Zhang M; Sun L; Liu H; Qian C; Yu S
    J Headache Pain; 2023 Aug; 24(1):103. PubMed ID: 37542222
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of galcanezumab for the prevention of episodic migraine: Results of the EVOLVE-2 Phase 3 randomized controlled clinical trial.
    Skljarevski V; Matharu M; Millen BA; Ossipov MH; Kim BK; Yang JY
    Cephalalgia; 2018 Jul; 38(8):1442-1454. PubMed ID: 29848108
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of Different Doses of Galcanezumab vs Placebo for Episodic Migraine Prevention: A Randomized Clinical Trial.
    Skljarevski V; Oakes TM; Zhang Q; Ferguson MB; Martinez J; Camporeale A; Johnson KW; Shan Q; Carter J; Schacht A; Goadsby PJ; Dodick DW
    JAMA Neurol; 2018 Feb; 75(2):187-193. PubMed ID: 29255900
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tolerability and safety of galcanezumab in patients with chronic cluster headache with up to 15 months of galcanezumab treatment.
    Láinez MJA; Schoenen J; Stroud C; Bardos J; Bangs M; Kemmer P; Wenzel R; Kuruppu DK; Martinez JM; Oakes TM
    Headache; 2022 Jan; 62(1):65-77. PubMed ID: 34806783
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety of galcanezumab in patients with episodic migraine: A randomized placebo-controlled dose-ranging Phase 2b study.
    Oakes TMM; Skljarevski V; Zhang Q; Kielbasa W; Hodsdon ME; Detke HC; Camporeale A; Saper JR
    Cephalalgia; 2018 May; 38(6):1015-1025. PubMed ID: 29310444
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in acute headache medication use and health care resource utilization: Results from a randomized, double-blind, placebo-controlled clinical trial evaluating galcanezumab in adults with treatment-resistant migraine (CONQUER).
    Ambrosini A; Estemalik E; Pascual J; Rettiganti M; Stroud C; Day K; Ford J
    J Manag Care Spec Pharm; 2022 Jun; 28(6):645-656. PubMed ID: 35451858
    [No Abstract]   [Full Text] [Related]  

  • 18. 100% Response Rate to Galcanezumab in Patients With Episodic Migraine: A Post Hoc Analysis of the Results From Phase 3, Randomized, Double-Blind, Placebo-Controlled EVOLVE-1 and EVOLVE-2 Studies.
    Rosen N; Pearlman E; Ruff D; Day K; Jim Nagy A
    Headache; 2018 Oct; 58(9):1347-1357. PubMed ID: 30341990
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of galcanezumab on severity and symptoms of migraine in phase 3 trials in patients with episodic or chronic migraine.
    Ament M; Day K; Stauffer VL; Skljarevski V; Rettiganti M; Pearlman E; Aurora SK
    J Headache Pain; 2021 Feb; 22(1):6. PubMed ID: 33549036
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Galcanezumab in episodic migraine: subgroup analyses of efficacy by high versus low frequency of migraine headaches in phase 3 studies (EVOLVE-1 & EVOLVE-2).
    Silberstein SD; Stauffer VL; Day KA; Lipsius S; Wilson MC
    J Headache Pain; 2019 Jun; 20(1):75. PubMed ID: 31253091
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.